Literature DB >> 4171487

Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia.

O L Bijvoet, J van der Sluys Veer, A P Jansen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 4171487     DOI： 10.1016/s0140-6736(68)90236-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  34 in total

Review 1.  Calcitonin and calcitonin receptors: bone and beyond.

Authors:  M Pondel
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

2.  Medical staff conference. Paget disease of bone.

Authors: 
Journal:  West J Med       Date:  1978-09

3.  Paget's disease of bone: assessment and management.

Authors:  H K Ibbertson; T R Fraser; D J Scott; J C Cullen; J W Henley; E S Stephens; B Tait; D J Wattie
Journal:  Drugs       Date:  1979-07       Impact factor: 9.546

4.  Effect of calcitonin on different inflammatory models.

Authors:  S E Abdullahi; E A Martelli; E Bramm; L Franco; G P Velo
Journal:  Agents Actions       Date:  1977-12

5.  Increase of pain threshold by calcitonin during electrical stimulation of the dental pulp. Investigations in healthy volunteers with regard to plasma concentration.

Authors:  K Welzel; D Welzel
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

6.  Calcitonin resistance: clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins.

Authors:  J G Haddad; J G Caldwell
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

7.  Renal effects of calcitonin and parathyroid extract in man. Studies in hypoparathyroidism.

Authors:  H G Haas; M A Dambacher; J Guncaga; T Lauffenbruger
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

8.  Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.

Authors:  J Y Reginster; S Gaspar; R Deroisy; B Zegels; P Franchimont
Journal:  Osteoporos Int       Date:  1993-09       Impact factor: 4.507

9.  Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits.

Authors:  J Y Reginster; M Azria; S Gaspar; M Bleicher; N Franchimont; M Behhar; A Albert; P Franchimont
Journal:  Calcif Tissue Int       Date:  1992-06       Impact factor: 4.333

Review 10.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.